E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Coronary-artery stents : gauging, gorging, and gouging
TL;DR: Coronary stenting is now the predominant form of nonsurgical myocardial revascularization and accounts for well over 60 percent of the percutaneous coronary-revascularization procedures performed in hospitals around the world.
Journal ArticleDOI
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial.
TL;DR: The role of enhanced antiplatelet protection through pretreatment with the platelet ADP-receptor antagonist ticlopidine in preventing both the early and late complications of coronary stenting has not previously been explored as mentioned in this paper.
Journal ArticleDOI
Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
David C. Sane,D.C. Stump,Eric J. Topol,Kristina N. Sigmon,Walter K. Clair,Dean J. Kereiakes,Barry S. George,M F Stoddard,Eric R. Bates,Richard S. Stack +9 more
TL;DR: Black patients have an apparent enhanced sensitivity to rt-PA, which is manifested by increased thrombolytic efficacy, a more pronounced systemic fibrinogen breakdown, and increased transfusions.
Journal ArticleDOI
Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: Importance of coronary angioplasty
Eric J. Topol,James L. Weiss,Jeffrey A. Brinker,Kenneth P. Brin,Sidney O. Gottlieb,Lewis C. Becker,Bernadine H. Bulkley,Nisha Chandra,John T. Flaherty,Gary Gerstenblith,Sheldon H. Gottlieb,Alan D. Guerci,Pamela Ouyang,Michaelene P. Llewellyn,Myron L. Weisfeldt,Edward P. Shapiro +15 more
TL;DR: There was echocardiographically detectable improvement in function of reperfused infarct segments 10 days after coronary thrombolysis with recombinant tissue plasminogen activator.
Journal ArticleDOI
Minimal myocardial damage during coronary intervention is associated with impaired outcome.
Maarten L. Simoons,M. van den Brand,M. Lincoff,Robert A. Harrington,R. van der Wieken,A Vahanian,Wolfgang Rutsch,J. Kootstra,Eric Boersma,Robert M. Califf,Eric J. Topol +10 more
TL;DR: Moderate elevation of cardiac enzymes (creatine kinase-MB, creatine kinase) after percutaneous coronary intervention is associated with an increased risk of mortality and reinfarction during the 6 month follow-up, and measures to reduce such periprocedural infarcts are warranted.